Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Pacira second quarter total revenues increase to $3.6 million

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the second quarter ended June 30, 2011, provided an update on the execution of its pre-commercial and launch strategies for EXPAREL, and updated its 2011 financial guidance.

11 Aug 2011

China Pharma second quarter revenue increases 18% to $19.6 million

China Pharma Holdings, Inc., a specialty pharmaceuticals company in China, today announced financial results for the quarter ended June 30, 2011.

11 Aug 2011

InVivo Therapeutics reports net loss of $1,370,000 for second quarter 2011

InVivo Therapeutics Holdings Corp., a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today reported financial results for the three and six months ended June 30, 2011 and provided a business update.

11 Aug 2011

Moberg Derma receives first order for Emtrix from Walmart

The public company Moberg Derma AB has through its U.S. distributor Alterna LLC received a first order from the world's largest retail chain, Walmart, for Emtrix - its treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis.

10 Aug 2011

Akela announces new corporate focus on PharmaForm

Akela Pharma, Inc. today announced a new strategic focus on its profitable pharmaceutical contract manufacturing business, PharmaForm, LLC.

9 Aug 2011

A.P. Pharma second quarter net loss decreases to $1.9 million

A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2011 and highlighted its recent corporate progress.

8 Aug 2011

Unigene second quarter revenue decreases to $2.5 million

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced second quarter financial results for the period ended June 30, 2011. The Company highlighted significant progress achieved in the second quarter with the continued execution of its turnaround strategy.

8 Aug 2011

Alexza resubmits AZ-004 NDA for treatment of agitation in schizophrenia patients

Alexza Pharmaceuticals, Inc. announced today that it has resubmitted its AZ-004 New Drug Application (NDA) to the U.S. Food and Drug Administration in response to a Complete Response Letter (CRL) received in October 2010.

5 Aug 2011

Scientists confirm feasibility of new battery-powered skin patch drug delivery system

Scientists have confirmed the feasibility of using a new drug delivery system - the basis for a battery-powered skin patch - to administer medication that shows promise for treating peripheral artery disease (PAD) and healing stubborn skin ulcers and burns.

5 Aug 2011

World RNA Interference market will be worth $4 billion by 2017: New report

By 2017, the world RNA Interference market will be worth $4 billion, according to a new report available from companiesandmarkets.com.

5 Aug 2011

Columbia Laboratories second quarter total net revenues increase to $19.2 million

Columbia Laboratories, Inc. today reported financial results for the three- and six-month periods ended June 30, 2011.

4 Aug 2011

Aggressive medication leads to growth of drug-resistant pathogens

New research raises troubling concerns about the use of aggressive drug therapies to treat a wide range of diseases such as MRSA, C. difficile, malaria, and even cancer.

4 Aug 2011

NSF awards WSU researcher CAREER grant to develop neural implants

Neural implants have the potential to treat disorders and diseases that typically require long-term treatment, such as blindness, deafness, epilepsy, spinal cord injury, and Alzheimer's and Parkinson's. However, implantable devices have been problematic in clinical applications because of bodily reactions that limit device functioning time.

4 Aug 2011

Innovative delivery systems and methods to treat breast cancer

In their lifetime, women have more than a 12 percent risk of being diagnosed with breast cancer. 1 This week, research on novel approaches to breast cancer treatment is being presented at the Era of Hope (EOH) conference, a scientific meeting hosted by the Department of Defense Breast Cancer Research Program (BCRP).

4 Aug 2011

Aerogen receives Ruban d'Honneur award for global growth strategy

Irish company Aerogen, a medical device and drug delivery company has been awarded the internationally prestigious Ruban d'Honneur award in the European Business Awards.

3 Aug 2011

SXC enters definitive agreement to acquire PTRx

SXC Health Solutions Corp. announced today that it has entered into a definitive agreement to acquire PTRx, Inc., a full-service PBM, and SaveDirectRx, Inc., its exclusive mail-order pharmacy provider, both based in San Antonio.

3 Aug 2011

Needle-free nanopatch vaccine delivery system

The needle-free nanopatch vaccine delivery system is coming soon after a consortium of investors put up $15 million for its development. The money will enable University of Queensland's Professor Mark Kendall to continue his work on the technology. It is described as the biggest breakthrough in vaccine delivery since the invention of the syringe more than 150 years ago.

3 Aug 2011

Lipid nanocarriers in cancer diagnosis and therapy: New book

This book introduces fundamental principles of lipid nanocarriers science relevant to cancer therapy. The first in this field, it fills a need for an accurate, coherent and authoritative introduction to lipid nanocarriers focusing in cancer therapy; both because of the growing popularity of these modern drug delivery systems and also because of the emergent need of dealing with cancer treatment.

2 Aug 2011

BD third quarter revenues increase to $2.014 billion

BD, a leading global medical technology company, today reported quarterly revenues of $2.014 billion for the third fiscal quarter ended June 30, 2011, representing an increase of 10.0 percent from the prior-year period.

From BD (Becton, Dickinson and Company) 2 Aug 2011

Sigma-Tau, Soligenix expand partnership to develop and commercialize orBec in Europe

Soligenix, Inc., a late-stage biopharmaceutical company, announces the expansion and amendment of its North American licensing partnership with Sigma-Tau Pharmaceuticals, Inc. for the development and commercialization of orBec into the European territory.

29 Jul 2011